Catalent signs formulation and commercial supply agreement for Mantra oral gels
Company / institutional announcement · Catalent
Source published:
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Catalent and Mantra have signed a commercial supply agreement covering single-serve over-the-counter oral gels. Catalent will provide formulation development, manufacturing, and packaging at its St. Petersburg, Florida, facility for products addressing occasional sleeplessness, pain, and menstrual discomfort. The announcement establishes a development and supply relationship; it does not report new clinical efficacy data or regulatory approvals for the portfolio.
Why it may matter
Oral gels offer dosage-form differentiation in consumer health, creating formulation work around palatability, dose uniformity, and packaging compatibility for developers.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections